ABT
NYSEHealthcareLoading…
Abbott Laboratories Common Stock
Sector: Healthcare•United States•Market Cap: $182.2B
Related News
Latest stories connected to ABT
10/13More news →
- RS 68Reasons to Retain Abbott Stock in Your Portfolio NowZacks Investment Research•1d ago•Original source
- RS 68Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending StockZacks Investment Research•2d ago•Original source
- RS 68John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screeningPRNewsWire•Mar 24, 2026•Original source
- RS 68Is Trending Stock Abbott Laboratories (ABT) a Buy Now?Zacks Investment Research•Mar 18, 2026•Original source
- RS 68DGI For The DIY: 2025 Dividend Portfolio ReviewSeeking Alpha•Mar 17, 2026•Original source
- RS 68Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation SummitBusiness Wire•Mar 13, 2026•Original source
- RS 68Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementPRNewsWire•Mar 12, 2026•Original source
- RS 68Abbott (ABT) is a Top-Ranked Growth Stock: Should You Buy?Zacks Investment Research•Mar 10, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 44.33B | 41.95B | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B |
| Cost of Revenue | 19.72B | 20.63B | 20.07B | 21.33B | 19.86B | 17.23B | 15.21B | 14.76B | 14.32B | 9.61B |
| Gross Profit | 24.61B | 21.32B | 20.04B | 22.32B | 23.21B | 17.38B | 16.69B | 15.82B | 13.07B | 11.24B |
| Research and Development Expenses | 2.96B | 2.82B | 2.72B | 2.85B | 2.74B | 2.42B | 2.41B | 2.29B | 2.13B | 1.36B |
| General and Administrative Expenses | 12.38B | 0 | 0 | 0 | 0 | 0 | 0 | 9.74B | 9.12B | 6.67B |
| Selling and Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General and Administrative Expenses | 12.38B | 11.65B | 10.88B | 11.11B | 11.28B | 9.67B | 9.69B | 9.69B | 8.96B | 6.64B |
| Other Expenses | 1.25B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 16.59B | 14.47B | 13.60B | 13.96B | 14.01B | 12.09B | 12.10B | 11.98B | 11.09B | 8.00B |
| Cost and Expenses | 36.28B | 35.10B | 33.67B | 35.29B | 33.88B | 29.32B | 27.31B | 26.73B | 25.42B | 17.60B |
| Net Interest Income | -111.00M | -259.00M | -313.00M | -132.00M | -367.00M | -662.00M | -724.00M | -624.00M | -756.00M | -205.00M |
| Interest Income | 230.00M | 344.00M | 385.00M | 183.00M | 43.00M | 46.00M | 94.00M | 105.00M | 124.00M | 99.00M |
| Interest Expense | 341.00M | 603.00M | 698.00M | 315.00M | 410.00M | 708.00M | 818.00M | 729.00M | 880.00M | 304.00M |
| Depreciation and Amortization | 2.75B | 3.22B | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B |
| EBITDA | 11.33B | 10.83B | 10.61B | 11.89B | 12.16B | 9.00B | 7.91B | 6.88B | 6.13B | 3.07B |
| EBIT | 8.59B | 7.62B | 7.36B | 8.62B | 8.62B | 5.68B | 4.89B | 3.60B | 3.11B | 1.72B |
| Non Operating Income Excluding Interest | -538.00M | -765.00M | -927.00M | -259.00M | 579.00M | -385.00M | -304.00M | 242.00M | -1.14B | 1.53B |
| Operating Income | 8.05B | 6.83B | 6.43B | 8.36B | 9.20B | 5.29B | 4.59B | 3.84B | 1.97B | 3.25B |
| Total Other Income Expenses Net | 418.00M | 188.00M | 229.00M | -56.00M | -989.00M | -323.00M | -514.00M | -971.00M | 259.00M | -1.84B |
| Income Before Tax | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B |
| Income Tax Expense | 1.94B | -6.39B | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M |
| Net Income From Continuing Operations | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.47B | 3.69B | 2.33B | 353.00M | 1.06B |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 24.00M | 0 | 34.00M | 124.00M | 337.00M |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.38B |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 3.74 | 7.67 | 3.3 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 |
| EPS Diluted | 3.72 | 7.64 | 3.27 | 3.91 | 3.94 | 2.5 | 2.06 | 1.34 | 0.27 | 0.94 |
| Weighted Average SHS Out | 1.75B | 1.73B | 1.73B | 1.75B | 1.77B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B |
| Weighted Average SHS Out Dil | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.56 | 0.51 | 0.5 | 0.51 | 0.54 | 0.5 | 0.52 | 0.52 | 0.48 | 0.54 |
| R&D to Revenue | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 | 0.07 | 0.08 | 0.07 | 0.08 | 0.07 |
| SG&A to Revenue | 0.28 | 0 | 0 | 0 | 0 | 0 | 0 | 0.32 | 0.33 | 0.32 |
| Interest Burden | 0.96 | 0.92 | 0.91 | 0.96 | 0.95 | 0.88 | 0.83 | 0.8 | 0.72 | 0.82 |
| EBIT Margin | 0.2 | 0.18 | 0.18 | 0.2 | 0.2 | 0.16 | 0.15 | 0.12 | 0.11 | 0.08 |
| EBITDA Margin | 0.26 | 0.26 | 0.26 | 0.27 | 0.28 | 0.26 | 0.25 | 0.22 | 0.22 | 0.15 |
| EBT per EBIT | 1.05 | 1.03 | 1.04 | 0.99 | 0.89 | 0.94 | 0.89 | 0.75 | 1.13 | 0.43 |
| Effective Tax Rate | 0.23 | -0.91 | 0.14 | 0.17 | 0.14 | 0.1 | 0.1 | 0.19 | 0.84 | 0.25 |
| Tax Burden | 0.77 | 1.91 | 0.86 | 0.83 | 0.86 | 0.9 | 0.9 | 0.82 | 0.21 | 0.99 |
| Cont. Operations Profit Margin | 0.15 | 0.32 | 0.14 | 0.16 | 0.16 | 0.13 | 0.12 | 0.08 | 0.01 | 0.05 |
| Bottom Line Profit Margin | 0.15 | 0.32 | 0.14 | 0.16 | 0.16 | 0.13 | 0.11 | 0.08 | 0.02 | 0.07 |
| Operating Cycle | 185.37 | 169.87 | 179.22 | 157.62 | 149.74 | 173.81 | 165.63 | 155.76 | 161.71 | 149.31 |
| Fwd PEG Ratio | -0.65 | 0.11 | -2.05 | -36.74 | 0.61 | 1.99 | 0.78 | 0.13 | -2.91 | -0.59 |
| Earnings Yield | 0.03 | 0.07 | 0.03 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0 | 0.02 |
| Income Quality | 1.47 | 0.64 | 1.27 | 1.38 | 1.49 | 1.76 | 1.66 | 2.66 | 11.68 | 2.33 |